For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. We are guided by world-class scientists and business leaders whose great passion for innovation is equaled only by their focus and commitment to discover, develop and deliver medicines to the patients who depend on us.
